MOG antibody-associated disease (MOGAD)
MOG antibody-associated disease is an antibody-mediated CNS demyelinating disorder driven by IgG against myelin oligodendrocyte glycoprotein, the surface glycoprotein on oligodendrocyte processes that the antibody targets to drive complement-fixing and effector-mediated injury. The 2023 international consensus criteria (Banwell, Bennett, Marignier and colleagues) reclassified MOGAD as a distinct entity — separate from AQP4-positive neuromyelitis optica spectrum disorder, separate from multiple sclerosis, with its own diagnostic algorithm anchored on a reliable cell-based assay for MOG-IgG (live or fixed, NOT ELISA), characteristic MRI pattern, and clinical phenotype. Clinical phenotypes span optic neuritis (often bilateral, often with disc swelling, anterior and longitudinally extensive on orbits MRI), transverse myelitis, acute disseminated encephalomyelitis (ADEM, particularly in children), brainstem encephalitis, and cortical encephalitis with seizures. Roughly half of cases are monophasic; the other half relapse and require maintenance immunotherapy. There is no FDA-approved MOGAD-specific therapy as of 2026 — acute attacks are managed with high-dose IV methylprednisolone pulses plus IVIG plus plasma exchange for severe presentations, and relapsing disease is managed with rituximab, mycophenolate, azathioprine, tocilizumab, or monthly maintenance IVIG depending on the clinical pattern and the treating neuroimmunologist's read. Thirty-third deliberate non-elevation.
What changes during this transition
MOGAD is a distinct antibody-mediated CNS demyelinating disease, and that distinction is load-bearing for any conversation about adjunctive interventions — including peptides. The 2023 international consensus criteria from Banwell, Bennett, Marignier and colleagues separated MOGAD from AQP4+ NMOSD and from MS precisely because the antibody target, the MRI lesion pattern, the natural history, and the treatment response profile differ enough that bundling them under prior frameworks led to mistreatment. MOG-IgG targets myelin oligodendrocyte glycoprotein on the outer leaflet of oligodendrocyte processes; AQP4-IgG targets aquaporin-4 on astrocyte end-feet; MS has no single defining antibody. These are three different diseases, and the importance of that for /ask conversations is that evidence and standard-of-care from one does not automatically transfer to another. MOGAD's clinical phenotype skews toward optic neuritis (frequently bilateral, frequently with disc swelling on funduscopy, frequently anterior and longitudinally extensive on orbit MRI), transverse myelitis (often longitudinally extensive), ADEM (particularly in children — pediatric onset is common and ADEM-spectrum presentations are part of the MOGAD spectrum, not separate from it), brainstem encephalitis, and cortical encephalitis with seizures. Roughly half of adult and pediatric cases are monophasic — a single attack with recovery and no relapse over years of follow-up — and the recovery profile after a MOGAD attack is, on average, better than after an AQP4+ NMOSD attack, though attacks can still leave permanent visual or motor deficit. The other half are relapsing and need maintenance immunotherapy. There is no FDA-approved MOGAD-specific therapy as of 2026. Acute attacks are managed with high-dose IV methylprednisolone pulses (typically 1g daily for 3–5 days), often with IVIG added, and with plasma exchange for severe steroid-refractory presentations. Maintenance for relapsing disease is where the treatment landscape is most actively evolving: rituximab is the most-used agent and has the most evidence in MOGAD specifically, but its efficacy is notably less robust than in AQP4+ NMOSD — relapses on rituximab are not uncommon. Mycophenolate mofetil and azathioprine are conventional options. Tocilizumab (anti-IL-6 receptor) is emerging as a maintenance option, particularly for cases that relapse on B-cell depletion. Monthly maintenance IVIG has growing evidence and is particularly favored in pediatric MOGAD. Eculizumab and ravulizumab — both FDA-approved for AQP4+ NMOSD — are NOT validated for MOGAD. Inebilizumab's pivotal trial (N-MOmentum) included a MOG-positive subset that was underpowered to demonstrate efficacy. Satralizumab's pivotal trials (SAkuraStar, SAkuraSky) similarly included MOG-positive subsets without clear efficacy signal. The treatment landscape distinction matters because community sources sometimes blur 'NMOSD' and 'MOGAD' as if they were the same disease responding to the same agents — they aren't. Steroid-dependent MOGAD — relapse triggered by rapid steroid taper — is a recognized pattern, particularly in children. Slow tapers, sometimes with overlapping initiation of a maintenance agent, are the conventional response. Pediatric MOGAD specifically warrants its own editorial care. ADEM is a common MOGAD-spectrum presentation in children; pediatric onset is more frequent than in AQP4+ NMOSD; the pediatric demyelinating disease consortium has been building the pediatric-specific evidence base for over a decade. Pediatric MOGAD management is increasingly differentiated from adult management, including a stronger role for monthly IVIG as maintenance. Any peptide consideration in a pediatric MOGAD context carries the additional weight that pediatric safety data for peptides is, with rare exception, absent — the population is not the one peptide trials run in. MS disease-modifying therapies (interferons, fingolimod, natalizumab, ocrelizumab in MS-protocol use, dimethyl fumarate) are NOT indicated for MOGAD. The five peptides surfaced in /ask substrate here — BPC-157, Semax, Cerebrolysin, LL-37, NMN — are NOT MOGAD interventions and should not be presented to users as if they were. This is the 33rd deliberate non-elevation in the substrate program.
Important caveat
MOGAD is an antibody-mediated CNS demyelinating disease where misdiagnosis has consequences — misdiagnosis as MS leads to MS DMTs that are not indicated and may not work; misdiagnosis as AQP4+ NMOSD leads to eculizumab or ravulizumab that are not validated for MOGAD; missing the diagnosis entirely leads to untreated relapses with permanent visual or motor deficit. The 2023 international consensus criteria (Banwell, Bennett, Marignier et al.) require a cell-based assay for MOG-IgG — live or fixed CBA — because ELISA-based MOG testing has a false-positive rate too high to be diagnostically reliable. If a user encountered a 'positive MOG antibody' result on a test other than a cell-based assay, the correct next step is confirmation with a CBA at a reference laboratory, not initiating treatment. Acute MOGAD attacks are medical emergencies. Bilateral vision loss, transverse myelitis, ADEM presentations, brainstem syndromes, and cortical encephalitis with seizures all require urgent neurology evaluation and admission — high-dose IV methylprednisolone within hours-to-days of symptom onset materially affects recovery profile, and plasma exchange for severe presentations adds further benefit. No peptide intervention, no adjunct, no supplement substitutes for that acute care pathway. Maintenance immunotherapy for relapsing MOGAD is the load-bearing intervention and the choice (rituximab, mycophenolate, azathioprine, tocilizumab, monthly IVIG) belongs to the neuroimmunology team. Eculizumab, ravulizumab, inebilizumab, and satralizumab are not standard MOGAD agents — eculizumab and ravulizumab are AQP4+ NMOSD drugs not validated for MOGAD; inebilizumab and satralizumab had underpowered MOG-positive subsets in their pivotal NMOSD trials. STEROID TAPER DESERVES SPECIFIC PATIENT AWARENESS. Steroid-dependent MOGAD — relapse on rapid taper — is a recognized pattern. Tapers are individualized and managed by the treating neurologist; community advice on 'tapering off steroids quickly to add a peptide' is precisely the wrong direction. For pediatric MOGAD, the population question dominates. Pediatric peptide safety data is, with rare exception, absent. A child on rituximab plus IVIG plus a corticosteroid course is on a regimen designed and dosed by pediatric neuroimmunology — adjunct peptide conversations in that context belong with the treating pediatric neurologist, not with a peptide-clinic referral. Patient organizations — the Sumaira Foundation, the MOG Project, the Guthy-Jackson Charitable Foundation, and the Pediatric Demyelinating Disease Consortium for pediatric-specific resources — are real sources of patient-community support and education. None of them recommend peptides for MOGAD. WADA athletes: BPC-157 (S0) prohibited at all times.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.